On July 30, the official website of the Ministry of Commerce released the ''Statistical Analysis Report on the Operation of the Pharmaceutical Circulation Industry in 2020 ''(hereinafter referred to as the ''Report''), which is the overall scale of my country's pharmaceutical circulation industry, corporate benefits, sales area distribution ownership structure, and pharmaceutical e-commerce operations., Listed companies, registered licensed pharmacists and other ten dimensions of development and operational characteristics were analyzed, and the future development trend was predicted.The "Report" shows that with the continuous deepening of the reform of the medical and health system, the pharmaceutical distribution industry has accelerated the pace of transformation and upgrading, the total sales of the industry has increased steadily, and the degree of intensification has continued to increase,Continue to maintain a steady and positive trend. Total sales of seven major categories of pharmaceutical commodities nationwide in 202024149Billions of dollars, net of non-comparable factors YoY growth2.4%, growth slowed year-on-year6.2percentage point. Among them, the pharmaceutical retail market5119Billions of dollars, net of non-comparable factors YoY growth10.1%, the growth rate accelerated year-on-year0.2percentage point.

Image source: 2020 drug circulation industry operation statistical analysis report.

From the overall operating characteristics, the performance of the four types of enterprises in the pharmaceutical distribution industry can be said to have their own advantages:

The concentration of pharmaceutical wholesale enterprises continued to increase, and sales showedpick upSituation;

Sales of pharmaceutical retail enterprises rose steadily and increased.higherthe overall level of the industry;

Pharmaceutical logistics enterprises to enhance service capabilities and promote the coordinated development of the supply chain;

Pharmaceutical e-commerce salesGrowth, and offline integration into a new stage of development.

Retail business growth higher than the overall level

The future needs innovative models to meet demand

The sudden onset of the new coronary pneumonia epidemic in 2020 has had a significant impact on the development of all walks of life in China, unlike the slowdown in sales growth of large pharmaceutical wholesale companies, the 2020The sales of pharmaceutical retail enterprises throughout the year have been steadily rising and the situation is good.Total sales of the top 100 pharmaceutical retail enterprises1806Billions of dollars, accounting for the total national retail market35.3%, year-on-year improvement0.4percentage point. Among them, the top 10 total sales1071Billions of dollars, accounting for the total national retail market20.9%, up 1.3 percentage points year-on-year, the strong Hengqiang competition pattern is becoming clearer.

The growth rate of pharmaceutical retail enterprises is obviously due to its becoming an important place for people to purchase medical protection materials and related drugs for epidemic prevention during the epidemic. The report believes that pharmaceutical retail enterprises in a timely mannerAdjust the category structure to meet the market demandSales of family medical devices and large health care varieties increased significantly. At the same time, pharmaceutical retail enterprises are actively exploring the path of professional, digital and intelligent transformation,Improve service capacity, establish professional pharmacy, and provide health consultation and other special pharmaceutical services; With the help of digital information and intelligent means, it provides consumers with online and offline value-added services of B2C, O2O and "Internet", which has driven the continuous growth of retail market sales.

Photo Source: Photo Network

The Report predicts that in 2021, as people pay more attention to health, preventive demand will grow, as well as policies such as Internet health insurance payments and the "dual channel" of national health insurance negotiation drugs, will provide new opportunities for the development of retail pharmacies. At the same time, the reform of medical insurance payment methods, cross-border capital entry, and the development of pharmaceutical e-commerce have made the pharmaceutical retail industry more competitive. ThereforeThe Report recommends that:

1. Enterprises should seek new growth methods, accelerate digital transformation, intelligent upgrading, and carry out online and offline integrationMatch the individual needs of different consumers;

2. Continue to innovate business models, develop professional pharmacies, smart pharmacies and other models, and provide health monitoring, device rehabilitation, medical extension, chronic disease management and other service functions,To meet the diverse needs of consumer health services.

Pharmaceutical e-commerce sales doubled

High business expense ratio

According to incomplete statistics, the total sales of pharmaceutical e-commerce direct reporting enterprises in 2020 will reach1778Billions of dollars(including third-party trading service platform transactions), accounting for the total size of the national pharmaceutical market during the same period.7.4%, double the 2017 data. Among them, the transaction volume of the third-party transaction service platform is 70.8 billion yuan, accounting for 39.8 of the total sales of pharmaceutical e-commerce; B2B (business-to-business) business sales are 100.3 billion yuan, accounting for 56.4 of the total sales of pharmaceutical e-commerce; B2C (business-to-customer) business sales are 6.7 billion yuan, accounting for 3.8 of the total sales of pharmaceutical e-commerce.

As you can see,at the present stageB2BBusiness is still the main force in the pharmaceutical e-commerce sector.The B2C business is at a relative disadvantage. However, from the point of view of the number of active users of the website, B2C websites take the lead with 49.53 million active users and have great potential.

The report points out that B2B business is mainly concentrated in western medicine, followed by Chinese patent medicine, while B2C business is mainly concentrated in western medicine and medical equipment, followed by other categories including health products, cosmetics and personal care products, family planning and adult products. In addition, it is worth noting that B2B and B2C e-commerce business expense rates are still high, reaching 7.3 and 16.3 respectively, both higher than the industry average expense rate of 6.8.

The industry generally believes that with the future landing of the prescription drug online sales policy, the "fourth terminal" is bound to usher in a new stage of development opportunities. The "Report" predicts that under the guidance of national policies, pharmaceutical e-commerce will move towards a standardized development path. In the future, social capital will continue to enter the field of pharmaceutical e-commerce, making it a diversified competitive situation.Traditional pharmaceutical circulation enterprises should actively respond to the challenges, accelerate the transformation of retail business from offline to online and offline integration, and form a new pattern of integration and competitive development with pharmaceutical e-commerce.

Source: Medical Economic News